Catalent Stock Surges on Report of Danaher Interest

Catalent


stock surged nearly 25% in premarket trading Monday following a report that life sciences company


Danaher


has expressed interest in taking over the contract drug maker.

Catalent


(ticker: CTLT) was the sharpest riser in premarket trading on the possibility of the interest leading to a potential deal. The interest by


Danaher


(DHR), shown in recent months, values Catalent at a “significant premium,” Bloomberg reported, citing people familiar with the matter. It is unclear whether Catalent is receptive to an offer, the report added, clarifying that a deal wasn’t imminent.